Literature DB >> 19953639

Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations.

Alessandra Pangrazio1, Michael Pusch, Elena Caldana, Annalisa Frattini, Edoardo Lanino, Parag M Tamhankar, Shubha Phadke, Antonio Gonzalez Meneses Lopez, Paul Orchard, Ercan Mihci, Mario Abinun, Michael Wright, Kim Vettenranta, Ivo Bariae, Daniela Melis, Ilhan Tezcan, Clarisse Baumann, Franco Locatelli, Marco Zecca, Edwin Horwitz, Lamia Sfaihi Ben Mansour, Mirjam Van Roij, Paolo Vezzoni, Anna Villa, Cristina Sobacchi.   

Abstract

The "Osteopetroses" are genetic diseases whose clinical picture is caused by a defect in bone resorption by osteoclasts. Three main forms can be distinguished on the basis of severity, age of onset and means of inheritance: the dominant benign, the intermediate and the recessive severe form. While several genes have been involved in the pathogenesis of the different types of osteopetroses, the CLCN7 gene has drawn the attention of many researchers, as mutations within this gene are associated with very different phenotypes. We report here the characterization of 25 unpublished patients which has resulted in the identification of 20 novel mutations, including 11 missense mutations, 6 causing premature termination, 1 small deletion and 2 putative splice site defects. Careful analysis of clinical and molecular data led us to several conclusions. First, intermediate osteopetrosis is not homogeneous, since it can comprise both severe dominant forms with an early onset and recessive ones without central nervous system involvement. Second, the appropriateness of haematopoietic stem cell transplantation in CLCN7-dependent ARO patients has to be carefully evaluated and exhaustive CNS examination is strongly suggested, as transplantation can almost completely cure the disease in situations where no primary neurological symptoms are present. Finally, the analysis of this largest cohort of CLCN7-dependent ARO patients together with some ADO II families allowed us to draw preliminary genotype-phenotype correlations suggesting that haploinsufficiency is not the mechanism causing ADO II. The availability of biochemical assays to characterize ClC-7 function will help to confirm this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19953639     DOI: 10.1002/humu.21167

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  31 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Partial depletion of TCR alpha/beta(+)/ CD19(+) cells in matched unrelated transplantation of three patients with osteopetrosis.

Authors:  F Porta; S Cavagnini; L Imberti; A Sottini; F Bolda; A Beghin; A Caruso; A Lanfranchi
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

3.  Genotyping, generation and proteomic profiling of the first human autosomal dominant osteopetrosis type II-specific induced pluripotent stem cells.

Authors:  Minglin Ou; Chunhong Li; Donge Tang; Wen Xue; Yong Xu; Peng Zhu; Bo Li; Jiansheng Xie; Jiejing Chen; Weiguo Sui; Lianghong Yin; Yong Dai
Journal:  Stem Cell Res Ther       Date:  2019-08-14       Impact factor: 6.832

4.  Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADO-II) and intermediate autosomal recessive osteopetrosis (IARO) in Chinese patients.

Authors:  Q Pang; Y Chi; Z Zhao; X Xing; M Li; O Wang; Y Jiang; R Liao; Y Sun; J Dong; W Xia
Journal:  Osteoporos Int       Date:  2015-09-22       Impact factor: 4.507

5.  Hematopoietic cell transplantation for a child with OSTM1 osteopetrosis.

Authors:  Kathleen M Overholt; Melissa J Rose; Sarita Joshi; Gail E Herman; Rajinder Bajwa; Rolla Abu-Arja; Hemalatha G Rangarajan; Edwin M Horwitz
Journal:  Blood Adv       Date:  2016-12-30

6.  Whole exome sequencing identified two novel homozygous missense variants in the same codon of CLCN7 underlying autosomal recessive infantile malignant osteopetrosis in a Pakistani family.

Authors:  Muhammad Aman Khan; Aman Ullah; Muhammad Naeem
Journal:  Mol Biol Rep       Date:  2018-06-20       Impact factor: 2.316

7.  Two novel mutations of CLCN7 gene in Chinese families with autosomal dominant osteopetrosis (type II).

Authors:  Hui Zheng; Chong Shao; Yan Zheng; Jin-Wei He; Wen-Zhen Fu; Chun Wang; Zhen-Lin Zhang
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

8.  ClC-7 is a slowly voltage-gated 2Cl(-)/1H(+)-exchanger and requires Ostm1 for transport activity.

Authors:  Lilia Leisle; Carmen F Ludwig; Florian A Wagner; Thomas J Jentsch; Tobias Stauber
Journal:  EMBO J       Date:  2011-04-28       Impact factor: 11.598

Review 9.  Osteopetrosis: genetics, treatment and new insights into osteoclast function.

Authors:  Cristina Sobacchi; Ansgar Schulz; Fraser P Coxon; Anna Villa; Miep H Helfrich
Journal:  Nat Rev Endocrinol       Date:  2013-07-23       Impact factor: 43.330

10.  Structure of a eukaryotic CLC transporter defines an intermediate state in the transport cycle.

Authors:  Liang Feng; Ernest B Campbell; Yichun Hsiung; Roderick MacKinnon
Journal:  Science       Date:  2010-09-30       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.